<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37567910</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Mesenchymal stem cells enhance CCL8 expression by podocytes in lupus-prone MRL.Fas<sup>lpr</sup> mice.</ArticleTitle><Pagination><StartPage>13074</StartPage><MedlinePgn>13074</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13074</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-40346-8</ELocationID><Abstract><AbstractText>Nephritis is common in systemic lupus erythematosus patients and is associated with hyper-activation of immune and renal cells. Although mesenchymal stem cells (MSCs) ameliorate nephritis by inhibiting T and B cells, whether MSCs directly affect renal cells is unclear. To address this issue, we examined the direct effect of MSCs on renal cells with a focus on chemokines. We found that expression of CCL2, CCL3, CCL4, CCL5, CCL8, CCL19, and CXCL10 increased 1.6-5.6-fold in the kidney of lupus-prone MRL.Fas<sup>lpr</sup> mice with advancing age from 9 to 16&#xa0;weeks. Although MSCs inhibited the increase in the expression of most chemokines by 52-95%, they further increased CCL8 expression by 290%. Using renal cells, we next investigated how MSCs enhanced CCL8 expression. CCL8 was expressed by podocytes, but not by tubular cells. MSCs enhanced CCL8 expression by podocytes in a contact-dependent manner, which was proved by transwell assay and blocking with anti-VCAM-1 antibody. Finally, we showed that CCL8 itself activated MSCs to produce more immunosuppressive factors (IL-10, IDO, TGF-&#x3b2;1, and iNOS) and to inhibit more strongly IFN-&#x3b3; production by T cells. Taken together, our data demonstrate that MSCs activate podocytes to produce CCL8 in a contact-dependent manner and conversely, podocyte-derived CCL8 might potentiate immunosuppressive activity of MSCs in a paracrine fashion. Our study documents a previously unrecognized therapeutic mechanism of MSCs in nephritis.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Hyung Sook</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology and Biomedicine, Chungbuk Provincial University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>Hong Kyung</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioengineering Institute, Corestem Inc., Gyeonggi, 13486, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kihyeon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Gi Beom</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Sung</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioengineering Institute, Corestem Inc., Gyeonggi, 13486, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Tae Yong</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioengineering Institute, Corestem Inc., Gyeonggi, 13486, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Dong Ju</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Youngsoo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Jin Tae</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Sang-Bae</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, 28160, Republic of Korea. shan@chungbuk.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515454">Ccl8 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050199" MajorTopicYN="Y">Podocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>12</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37567910</ArticleId><ArticleId IdType="pmc">PMC10421856</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-40346-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-40346-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann. Rheum. Dis. 2017;76:1436&#x2013;1439. doi: 10.1136/annrheumdis-2017-211073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211073</ArticleId><ArticleId IdType="pubmed">28478399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 2012;14(Suppl 4):S4. doi: 10.1186/ar3919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3919</ArticleId><ArticleId IdType="pmc">PMC3535719</ArticleId><ArticleId IdType="pubmed">23281889</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Pirapakaran T, Luo XM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediat. Inflamm. 2016;2016:6012715. doi: 10.1155/2016/6012715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/6012715</ArticleId><ArticleId IdType="pmc">PMC4923605</ArticleId><ArticleId IdType="pubmed">27403037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lech M, Anders HJ. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 2013;24:1357&#x2013;1366. doi: 10.1681/ASN.2013010026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2013010026</ArticleId><ArticleId IdType="pmc">PMC3752952</ArticleId><ArticleId IdType="pubmed">23929771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha S, Chung KW, Lee J, Chung HY, Moon HR. Renal tubular PAR2 promotes interstitial fibrosis by increasing inflammatory responses and EMT process. Arch. Pharm. Res. 2022;45:159&#x2013;173. doi: 10.1007/s12272-022-01375-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-022-01375-5</ArticleId><ArticleId IdType="pubmed">35334088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front. Biosci. 2008;13:3312&#x2013;3320. doi: 10.2741/2927.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2927</ArticleId><ArticleId IdType="pubmed">18508434</ArticleId></ArticleIdList></Reference><Reference><Citation>Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J. Am. Soc. Nephrol. 2000;11:152&#x2013;176. doi: 10.1681/ASN.V111152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V111152</ArticleId><ArticleId IdType="pubmed">10616852</ArticleId></ArticleIdList></Reference><Reference><Citation>Banas MC, et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J. Am. Soc. Nephrol. 2008;19:704&#x2013;713. doi: 10.1681/ASN.2007040395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2007040395</ArticleId><ArticleId IdType="pmc">PMC2390962</ArticleId><ArticleId IdType="pubmed">18256364</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CH, et al. Effects of tumor necrosis factor-alpha on podocyte expression of monocyte chemoattractant protein-1 and in diabetic nephropathy. Nephron Extra. 2015;5:1&#x2013;18. doi: 10.1159/000369576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000369576</ArticleId><ArticleId IdType="pmc">PMC4369122</ArticleId><ArticleId IdType="pubmed">25852733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarsenova M, et al. Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells. Front. Immunol. 2022;13:1010399. doi: 10.3389/fimmu.2022.1010399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1010399</ArticleId><ArticleId IdType="pmc">PMC9537745</ArticleId><ArticleId IdType="pubmed">36211399</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, et al. Improving the immunomodulatory function of mesenchymal stem cells by defined chemical approach. Front. Immunol. 2022;13:1005426. doi: 10.3389/fimmu.2022.1005426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1005426</ArticleId><ArticleId IdType="pmc">PMC9530344</ArticleId><ArticleId IdType="pubmed">36203584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, et al. CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms. Sci. Rep. 2017;7:41258. doi: 10.1038/srep41258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep41258</ArticleId><ArticleId IdType="pmc">PMC5259742</ArticleId><ArticleId IdType="pubmed">28117437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, et al. Effect of human mesenchymal stem cells on xenogeneic T and B cells isolated from lupus-prone MRL.Fas (lpr) mice. Stem Cells Int. 2020;2020:5617192. doi: 10.1155/2020/5617192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5617192</ArticleId><ArticleId IdType="pmc">PMC7077055</ArticleId><ArticleId IdType="pubmed">32215018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, et al. Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas(lpr) mice. Theranostics. 2020;10:10186&#x2013;10199. doi: 10.7150/thno.46835.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.46835</ArticleId><ArticleId IdType="pmc">PMC7481409</ArticleId><ArticleId IdType="pubmed">32929342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bromley SK, et al. The immunological synapse. Annu. Rev. Immunol. 2001;19:375&#x2013;396. doi: 10.1146/annurev.immunol.19.1.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.19.1.375</ArticleId><ArticleId IdType="pubmed">11244041</ArticleId></ArticleIdList></Reference><Reference><Citation>She S, et al. Functional roles of chemokine receptor CCR2 and its ligands in liver disease. Front. Immunol. 2022;13:812431. doi: 10.3389/fimmu.2022.812431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.812431</ArticleId><ArticleId IdType="pmc">PMC8913720</ArticleId><ArticleId IdType="pubmed">35281057</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med. 1999;190:1813&#x2013;1824. doi: 10.1084/jem.190.12.1813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.190.12.1813</ArticleId><ArticleId IdType="pmc">PMC2195716</ArticleId><ArticleId IdType="pubmed">10601356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacotte S, et al. Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS ONE. 2013;8:e58140. doi: 10.1371/journal.pone.0058140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0058140</ArticleId><ArticleId IdType="pmc">PMC3592892</ArticleId><ArticleId IdType="pubmed">23520491</ArticleId></ArticleIdList></Reference><Reference><Citation>Balabanian K, et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J. Immunol. 2003;170:3392&#x2013;3400. doi: 10.4049/jimmunol.170.6.3392.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.6.3392</ArticleId><ArticleId IdType="pubmed">12626600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignon A, et al. CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice. J. Immunol. 2014;192:886&#x2013;896. doi: 10.4049/jimmunol.1300123.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300123</ArticleId><ArticleId IdType="pubmed">24367031</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J. Am. Soc. Nephrol. 2004;15:1504&#x2013;1513. doi: 10.1097/01.ASN.0000130082.67775.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000130082.67775.60</ArticleId><ArticleId IdType="pubmed">15153561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanaoka H, et al. Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus. Clin. Exp. Rheumatol. 2015;33:863&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">26320881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W, Yousefi K, Shehadeh LA. Isolation, characterization, and high throughput extracellular flux analysis of mouse primary renal tubular epithelial cells. J. Vis. Exp. 2018;136:e57718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6101965</ArticleId><ArticleId IdType="pubmed">29985358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg A, Kanapathippillai P, Rekvig OP, Fenton KA. LMW heparin prevents increased kidney expression of proinflammatory mediators in (NZBxNZW)F1 mice. Clin. Dev. Immunol. 2013;2013:791262. doi: 10.1155/2013/791262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/791262</ArticleId><ArticleId IdType="pmc">PMC3789300</ArticleId><ArticleId IdType="pubmed">24151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, et al. Placental mesenchymal stem cells alleviate podocyte injury in diabetic kidney disease by modulating mitophagy via the SIRT1-PGC-1alpha-TFAM pathway. Int. J. Mol. Sci. 2023;24:4696. doi: 10.3390/ijms24054696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054696</ArticleId><ArticleId IdType="pmc">PMC10003373</ArticleId><ArticleId IdType="pubmed">36902127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Mesenchymal stem cell-derived exosomes ameliorate diabetic kidney disease through the NLRP3 signaling pathway. Stem Cells. 2023;41:368&#x2013;383. doi: 10.1093/stmcls/sxad010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/stmcls/sxad010</ArticleId><ArticleId IdType="pubmed">36682034</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, et al. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nat. Commun. 2017;8:983. doi: 10.1038/s41467-017-00937-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00937-2</ArticleId><ArticleId IdType="pmc">PMC5754365</ArticleId><ArticleId IdType="pubmed">29042548</ArticleId></ArticleIdList></Reference><Reference><Citation>Asano K, et al. Intestinal CD169(+) macrophages initiate mucosal inflammation by secreting CCL8 that recruits inflammatory monocytes. Nat. Commun. 2015;6:7802. doi: 10.1038/ncomms8802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8802</ArticleId><ArticleId IdType="pmc">PMC4518321</ArticleId><ArticleId IdType="pubmed">26193821</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam SA, et al. Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. Nat. Immunol. 2011;12:167&#x2013;177. doi: 10.1038/ni.1984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1984</ArticleId><ArticleId IdType="pmc">PMC3863381</ArticleId><ArticleId IdType="pubmed">21217759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Z, Lan T, Wei Y, Wei X. CCL5/CCR5 axis in human diseases and related treatments. Genes Dis. 2022;9:12&#x2013;27. doi: 10.1016/j.gendis.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2021.08.004</ArticleId><ArticleId IdType="pmc">PMC8423937</ArticleId><ArticleId IdType="pubmed">34514075</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu MM, et al. Increased serum RANTES in patients with systemic lupus erythematosus. Rheumatol. Int. 2012;32:1231&#x2013;1233. doi: 10.1007/s00296-010-1761-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1761-2</ArticleId><ArticleId IdType="pubmed">21258798</ArticleId></ArticleIdList></Reference><Reference><Citation>Horuk R. Chemokine receptor antagonists: Overcoming developmental hurdles. Nat. Rev. Drug Discov. 2009;8:23&#x2013;33. doi: 10.1038/nrd2734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2734</ArticleId><ArticleId IdType="pubmed">19079127</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar RD, et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 2006;17:141&#x2013;149. doi: 10.1681/ASN.2005070714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2005070714</ArticleId><ArticleId IdType="pubmed">16280469</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke J, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J. Am. Soc. Nephrol. 2008;19:1177&#x2013;1189. doi: 10.1681/ASN.2007111179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2007111179</ArticleId><ArticleId IdType="pmc">PMC2396941</ArticleId><ArticleId IdType="pubmed">18337479</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot AE, Bonvin P, Power CA. Targeting chemokines: Pathogens can, why can't we? Cytokine. 2015;74:259&#x2013;267. doi: 10.1016/j.cyto.2015.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2015.02.011</ArticleId><ArticleId IdType="pubmed">25753743</ArticleId></ArticleIdList></Reference><Reference><Citation>Marie MA, Abu Khalil RE, Habib HM. Urinary CXCL10: A marker of nephritis in lupus patients. Reumatismo. 2014;65:292&#x2013;297. doi: 10.4081/reumatismo.2013.719.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2013.719</ArticleId><ArticleId IdType="pubmed">24705033</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami A, et al. A novel method for isolating podocytes using magnetic activated cell sorting. Nephrol. Dial. Transpl. 2010;25:3884&#x2013;3890. doi: 10.1093/ndt/gfq323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfq323</ArticleId><ArticleId IdType="pubmed">20530496</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, et al. Effect of a combination of prednisone or mycophenolate mofetil and mesenchymal stem cells on lupus symptoms in MRL.Fas(lpr) mice. Stem Cells Int. 2018;2018:4273107. doi: 10.1155/2018/4273107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4273107</ArticleId><ArticleId IdType="pmc">PMC6051060</ArticleId><ArticleId IdType="pubmed">30057623</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida N, et al. Beneficial effects of systemically administered human muse cells in adriamycin nephropathy. J. Am. Soc. Nephrol. 2017;28:2946&#x2013;2960. doi: 10.1681/ASN.2016070775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016070775</ArticleId><ArticleId IdType="pmc">PMC5619953</ArticleId><ArticleId IdType="pubmed">28674043</ArticleId></ArticleIdList></Reference><Reference><Citation>Breggia AC, Himmelfarb J. Primary mouse renal tubular epithelial cells have variable injury tolerance to ischemic and chemical mediators of oxidative stress. Oxid. Med. Cell. Longev. 2008;1:33&#x2013;38. doi: 10.4161/oxim.1.1.6491.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/oxim.1.1.6491</ArticleId><ArticleId IdType="pmc">PMC2715195</ArticleId><ArticleId IdType="pubmed">19794906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, et al. Cytokine-induced killer cells interact with tumor lysate-pulsed dendritic cells via CCR5 signaling. Cancer Lett. 2016;378:142&#x2013;149. doi: 10.1016/j.canlet.2016.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2016.05.020</ArticleId><ArticleId IdType="pubmed">27216980</ArticleId></ArticleIdList></Reference><Reference><Citation>Park EJ, et al. CD48-expressing non-small-cell lung cancer cells are susceptible to natural killer cell-mediated cytotoxicity. Arch. Pharm. Res. 2022;45:1&#x2013;10. doi: 10.1007/s12272-021-01365-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-021-01365-z</ArticleId><ArticleId IdType="pubmed">34905179</ArticleId></ArticleIdList></Reference><Reference><Citation>Won Jun H, et al. The role of CCL2, CCL7, ICAM-1, and VCAM-1 in interaction of endothelial cells and natural killer cells. Int. Immunopharmacol. 2022;113:109332. doi: 10.1016/j.intimp.2022.109332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109332</ArticleId><ArticleId IdType="pubmed">36274485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, et al. CXCR3-deficient mesenchymal stem cells fail to infiltrate into the nephritic kidney and do not ameliorate lupus symptoms in MRL.Fas(lpr) mice. Lupus. 2018;27:1854&#x2013;1859. doi: 10.1177/0961203318794871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318794871</ArticleId><ArticleId IdType="pubmed">30139297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>